Lava Therapeutics B.V. (LVTX) has experienced a decline of 13.92% in the aftermarket. However, the last trading session concluded at $7.11 with an incline of 16.94%.
LVTX to Present its Bispecific Gamma Delta T Cell Engagers
On 7th October 2021, LVTX announced that the chief scientific officer, Hans van der Vliet, will speak at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. The Conference will take place within 7-10th October 2021.
Furthermore, Gamma delta T cells play an essential role in antitumor immunity. Hans is excited to present the platform approach to leveraging the powerful and precise anticancer capabilities of V9V2 T cells. He will also disclose the preclinical results from the LVTX program revealing an appealing therapeutic window that supports going into the clinic last quarter.
Second Quarter 2021 Financial Results
LVTX reported second-quarter 2021 financial results on 16th August 2021. As of June 30, 2021, cash and cash equivalents were €128.4 million, up from €12.9 million at the end of 2020. Moreover, proceeds from the Series C funding and subsequent IPO during the first quarter of 2021 contributed to the growth in cash and cash equivalents of LVTX, which was somewhat offset by operational expenditures.
Moreover, the research and license revenue grew to €0.9 million and €1.8 million, respectively, compared to €0.6 million and €1.8 million for the same period last year. Increases in personnel and expenditures connected with the start of our LAVA-051 clinical study contributed to the rise for the three months. Lastly, general, and administrative expenditures were €1.9 million and €3.3 million, respectively.
New Appointment to LPTX
LPTX announced the new appointments in the company on 27th July 2021. Amy Garabedian is the new general attorney and corporate secretary. Ms. Garabedian is a seasoned executive in the life sciences business with substantial corporate and transactional experience. LVTX welcomes Amy to the executive team with great pleasure. Amy’s demonstrated expertise in a wide range of complex strategic legal and corporate matters.
Amy Garabedian has over 15 years of expertise advising pharmaceutical and biopharmaceutical firms. Moreover, Ms Garabedian was most recently an associate general counsel at Spark Therapeutics (Roche). There she assisted in the official start of the first gene therapy in the United States. She also oversaw key business development transactions that enabled preclinical, clinical, and standalone executable development.
